A study of the detection of potential adverse drug events or interactions found that using PGx information led to better prediction of serious issues, despite no significant change overall.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
In the I-SPY 2 trial, investigators analyzed whether MammaPrint scores and BluePrint subtypes could help identify patients who would respond better to treatments.
Stanford University's Michael Snyder found that methylome shifts preceded spikes in his blood glucose levels, suggesting profiling could detect disease.
